(Q73270056)
Statements
Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma) (English)
M R Sertoli
P Queirolo
E Bajetta
M Del Vecchio
G Comella
L Barduagni
M G Bernengo
S Vecchio
D Criscuolo
R Bufalino
A Morabito
N Cascinelli
1 October 1999